These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 427766)

  • 21. The role of T, B and adherent cells in the in vitro immune response of TEPC-183-bearing mice.
    Patel M; Havas HF
    Immunology; 1982 May; 46(1):97-105. PubMed ID: 6978846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
    Mokyr MB; Rubin M; Newell KA; Prokhorova A; Bluestone JA
    J Immunol; 1993 Nov; 151(9):4838-46. PubMed ID: 8409442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incorporation of 125-I-iododeoxyuridine into target cells as an assay for cell immunity.
    Fish F; Yaakubovicz M; Witz IP
    J Natl Cancer Inst; 1974 Dec; 53(6):1743-7. PubMed ID: 4436870
    [No Abstract]   [Full Text] [Related]  

  • 24. Two tumor models of curative adoptive chemoimmunotherapy using tumor-infiltrated spleen cells with potent antitumor cytotoxicity stimulated by antigen-sharing tumors.
    Laude M; Russo KL; Mokyr MB; Dray S
    Cancer Immunol Immunother; 1993 Jul; 37(2):89-96. PubMed ID: 8319246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of effector cells mediating antitumor activity in spleen cells of tumor-bearing mice.
    Fuyama S; Yamamoto H; Arai S
    Cancer Res; 1985 Sep; 45(9):4103-8. PubMed ID: 3875404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunosuppression in BALB/c mice bearing the plasmacytoma TEPC-183: massive increase in red pulp macrophages induced by the tumour.
    Joshua DE; Humphrey JH; Grennan D; Brown G
    Immunology; 1980 Jun; 40(2):223-8. PubMed ID: 7409859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a beta-adrenergic receptor mechanism and decreased TNF-alpha gene expression.
    Kalinichenko VV; Mokyr MB; Graf LH; Cohen RL; Chambers DA
    J Immunol; 1999 Sep; 163(5):2492-9. PubMed ID: 10452985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunosuppression in plasmacytoma: induction of suppressor cells.
    Chen Y; Hwang LT; Heller P
    Clin Exp Immunol; 1982 Jan; 47(1):191-6. PubMed ID: 6212173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. F1 hybrid resistance to murine plasmacytoma MOPC-70A: hybrid resistance to MOPC-70A controlled by a locus linked to H-2.
    Kaneko Y; Natsuume-Sakai S; Moriwaki K; Migita S
    J Immunol; 1980 Nov; 125(5):2031-8. PubMed ID: 7430619
    [No Abstract]   [Full Text] [Related]  

  • 30. Induction of macrophage antitumor activity by a mycobacterial fraction. In vivo and in vitro studies.
    Rashid G; Gittel H; Ben-Efraim S
    Anticancer Res; 1994; 14(3A):1083-7. PubMed ID: 8074454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of protective antitumor immune response against a murine plasmacytoma not curable by alkylating-drug treatment.
    Ophir R; Jackman A; Relyveld EH; Ben-Efraim S
    Anticancer Res; 1990; 10(1):231-5. PubMed ID: 2334133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of immune responses aginst the syngeneic ADJ-PC-5 plasmacytoma in BALB-c mice. III. Induction of specific T suppressor cells to the BALB/c plasmacytoma ADJ-PC-5 during early stages of tumorigenesis.
    Haubeck HD; Kölsch E
    Immunology; 1982 Nov; 47(3):503-10. PubMed ID: 6215340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The mode of action of splenic suppressor cells in murine plasmacytoma.
    Chen Y; Heller P
    Clin Exp Immunol; 1981 Sep; 45(3):514-22. PubMed ID: 6461449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Host response to myeloma: effect of syngeneic spleen cells on the growth and function of MOPC 104E myeloma in vitro.
    Miura T; Ghanta VK; Hiramoto RN
    Cancer Invest; 1990; 8(1):17-25. PubMed ID: 2350718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
    Mokyr MB; Hengst JC; Dray S
    Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Release of immunosuppressive factor(s) by MOPC-315 murine plasmacytoma cells: a possible mechanism of defence.
    Bomstein Y; Ophir R; Harshemes H; Ben-Efraim S
    Anticancer Res; 1993; 13(6A):2125-9. PubMed ID: 8297124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.
    Gorelik L; Rubin M; Prokhorova A; Mokyr MB
    J Immunol; 1995 Apr; 154(8):3941-51. PubMed ID: 7706732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The augmentation of in vitro and in vivo tumor-specific T cell-mediated immunity by amplifier T lymphocytes.
    Fujiwara H; Hamaoka T; Shearer GM; Yamamoto H; Terry WD
    J Immunol; 1980 Feb; 124(2):863-9. PubMed ID: 6965392
    [No Abstract]   [Full Text] [Related]  

  • 39. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
    Barker E; Mokyr MB
    Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Macrophage tumoricidal activity as a possible antitumor mechanism associated with the local injection of allogeneic spleen cells into rats.
    Kawase I; Komuta K; Namba M; Yokota S; Ogura T; Kishimoto S
    Cancer Res; 1986 Mar; 46(3):1047-54. PubMed ID: 3510719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.